Brookmont Capital Management Novo Nordisk A S Transaction History

Brookmont Capital Management

$194 Million
Q3 2024

A detailed history of Brookmont Capital Management transactions in Novo Nordisk A S stock. As of the latest transaction made, Brookmont Capital Management holds 39,413 shares of NVO stock, worth $4.26 Million. This represents 2.41% of its overall portfolio holdings.

Number of Shares

39,413

Previous 38,562 2.21%

Holding current value

$4.26 Million

Previous $5.5 Million 14.75%

% of portfolio

2.41%

Previous 3.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 16, 2024	BUY	$119.07 - $145.42 $101,328 - $123,752	851 Added 2.21%	39,413 $4.69 Million
Q2 2024 Jul 17, 2024	SELL	$122.71 - $146.91 $79,270 - $94,903	-646 Reduced 1.65%	38,562 $5.5 Million
Q1 2024 Apr 16, 2024	SELL	$102.11 - $135.92 $1.47 Million - $1.96 Million	-14,402 Reduced 26.86%	39,208 $5.03 Million
Q4 2023 Jan 18, 2024	SELL	$87.78 - $105.45 $207,863 - $249,705	-2,368 Reduced 4.23%	53,610 $5.55 Million
Q3 2023 Oct 12, 2023	BUY	$90.94 - $199.54 $2.52 Million - $5.54 Million	27,760 Added 98.38%	55,978 $5.09 Million
Q2 2023 Jul 13, 2023	SELL	$155.98 - $172.65 $3,899 - $4,316	-25 Reduced 0.09%	28,218 $4.57 Million
Q1 2023 Apr 11, 2023	SELL	$132.34 - $159.14 $1.18 Million - $1.42 Million	-8,906 Reduced 23.97%	28,243 $4.49 Million
Q4 2022 Feb 06, 2023	SELL	$102.55 - $135.33 $118,752 - $156,712	-1,158 Reduced 3.02%	37,149 $5.03 Million
Q3 2022 Oct 12, 2022	BUY	$95.28 - $116.93 $211,902 - $260,052	2,224 Added 6.16%	38,307 $3.82 Million
Q2 2022 Aug 15, 2022	SELL	$103.24 - $121.81 $461,999 - $545,099	-4,475 Reduced 11.03%	36,083 $4.02 Million
Q1 2022 May 09, 2022	SELL	$93.1 - $112.54 $931 - $1,125	-10 Reduced 0.02%	40,558 $4.5 Million
Q4 2021 Jan 27, 2022	SELL	$95.88 - $117.08 $171,337 - $209,221	-1,787 Reduced 4.22%	40,568 $4.54 Million
Q3 2021 Nov 15, 2021	SELL	$84.42 - $106.62 $84,082 - $106,193	-996 Reduced 2.3%	42,355 $4.07 Million
Q2 2021 Jul 19, 2021	SELL	$67.66 - $84.76 $1,082 - $1,356	-16 Reduced 0.04%	43,351 $3.63 Million
Q1 2021 Apr 15, 2021	SELL	$67.06 - $75.82 $24,409 - $27,598	-364 Reduced 0.83%	43,367 $2.92 Million
Q4 2020 Feb 04, 2021	SELL	$63.89 - $73.8 $87,401 - $100,958	-1,368 Reduced 3.03%	43,731 $3.06 Million
Q3 2020 Oct 16, 2020	BUY	$63.69 - $70.22 $45,028 - $49,645	707 Added 1.59%	45,099 $3.13 Million
Q2 2020 Jul 23, 2020	SELL	$58.54 - $67.94 $1.05 Million - $1.22 Million	-17,926 Reduced 28.77%	44,392 $2.91 Million
Q1 2020 Apr 28, 2020	SELL	$49.46 - $64.78 $133,739 - $175,165	-2,704 Reduced 4.16%	62,318 $3.75 Million
Q4 2019 Jan 22, 2020	SELL	$49.86 - $58.26 $320,549 - $374,553	-6,429 Reduced 9.0%	65,022 $3.76 Million
Q3 2019 Nov 07, 2019	SELL	$47.54 - $53.43 $1 Million - $1.13 Million	-21,064 Reduced 22.77%	71,451 $3.69 Million
Q2 2019 Jul 18, 2019	BUY	$46.79 - $52.47 $13,849 - $15,531	296 Added 0.32%	92,515 $4.72 Million
Q1 2019 Apr 16, 2019	BUY	$46.36 - $52.63 $2,225 - $2,526	48 Added 0.05%	92,219 $4.82 Million
Q4 2018 Feb 12, 2019	BUY	$41.54 - $47.25 $402,314 - $457,616	9,685 Added 11.74%	92,171 $4.25 Million
Q3 2018 Nov 08, 2018	SELL	$46.76 - $51.24 $4,114 - $4,509	-88 Reduced 0.11%	82,486 $3.89 Million
Q2 2018 Jul 19, 2018	BUY	$44.29 - $50.42 $86,896 - $98,924	1,962 Added 2.43%	82,574 $3.81 Million
Q1 2018 May 14, 2018	SELL	$48.49 - $58.14 $3.6 Million - $4.32 Million	-74,311 Reduced 47.97%	80,612 $3.97 Million
Q4 2017 Feb 12, 2018	BUY	$47.53 - $53.73 $2.76 Million - $3.12 Million	57,985 Added 59.82%	154,923 $8.32 Million
Q3 2017 Nov 13, 2017	BUY	$41.15 - $49.22 $3.99 Million - $4.77 Million	96,938	96,938 $4.67 Million

Others Institutions Holding NVO

# of Institutions

1,956

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $244B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookmont Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Brookmont Capital Management with notifications on news.

Account

Brookmont Capital Management Novo Nordisk A S Transaction History